NovoCure Ltd (FRA:038)
€ 16.225 -0.425 (-2.55%) Market Cap: 1.75 Bil Enterprise Value: 1.48 Bil PE Ratio: 0 PB Ratio: 5.23 GF Score: 69/100

Novocure Ltd at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 03:30PM GMT
Release Date Price: €84.5 (-0.65%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan. Welcome back for Day 2 of our very in-person health care conference. A little different format this year than in the past. You're not going to switch rooms for Q&A. So we're going to, after the presentation, just go seamlessly into Q&A. There's 2 ways to ask questions. You can raise your hand and some will bring you a mic. You can also submit questions electronically through our portal. We'll send it to that iPad up there, and I can read them off for the management team.

So with that out of the way, let me pass it over to NovoCure's Executive Chairman, Bill Doyle for the presentation.

William F. Doyle
NovoCure Limited - Executive Chairman

Thank you, Jess. Good morning, everyone. Welcome to the Sunrise session at JPMorgan. I wasn't sure whether they'd actually be anybody in the room or not at 7:30. So I'm pleased to see everyone. I'll be making forward-looking statements.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot